Evolocumab is a monoclonal antibody that functions as a PCSK9 inhibitor, primarily used in the treatment of hyperlipidemia and cardiovascular diseases. It is designed to lower low-density lipoprotein (LDL) cholesterol levels by inhibiting the protein PCSK9, which plays a crucial role in the regulation of LDL receptors on liver cells. This inhibition leads to increased uptake of LDL cholesterol from the bloodstream, thereby reducing overall cholesterol levels. Evolocumab is administered via subcutaneous injection and is typically prescribed for patients who have not achieved adequate cholesterol control through diet and statin therapy alone. The substance is characterized by its high specificity for PCSK9, a human IgG2 monoclonal antibody structure, and a relatively long half-life, allowing for less frequent dosing. Common side effects may include injection site reactions, flu-like symptoms, and allergic reactions. As a biologic drug, evolocumab is subject to stringent regulatory oversight and is part of a broader class of therapies aimed at managing cholesterol levels effectively.

Evolocumab

1256937-27-5: Evolocumab is a monoclonal antibody that functions as a PCSK9 inhibitor, primarily used in the treatment of hyperlipidemia and cardiovascular diseases. It is designed to lower low-density lipoprotein (LDL) cholesterol levels by inhibiting the protein PCSK9, which plays a crucial role in the regulation of LDL receptors on liver cells. This inhibition leads to increased uptake of LDL cholesterol from the bloodstream, thereby reducing overall cholesterol levels. Evolocumab is administered via subcutaneous injection and is typically prescribed for patients who have not achieved adequate cholesterol control through diet and statin therapy alone. The substance is characterized by its high specificity for PCSK9, a human IgG2 monoclonal antibody structure, and a relatively long half-life, allowing for less frequent dosing. Common side effects may include injection site reactions, flu-like symptoms, and allergic reactions. As a biologic drug, evolocumab is subject to stringent regulatory oversight and is part of a broader class of therapies aimed at managing cholesterol levels effectively.

<p>Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9.Evolocumab can inhibit the binding of PCSK9 to LDLR.Cost-effective and quality-assured.</p>

<p>Inhibts PCSK9; hypercholesterolemia therapy</p>

CAS 1256937-27-5

Evolocumab

Evolocumab

Ref: TM-T9920

Evolocumab - solution - 5 mg/ml

Ref: 3D-BE165589